Table 2 The biochemical results before and after treatment of patients in different groups.

From: Long-term follow-up of Chinese patients with methylmalonic acidemia of the cblC and mut subtypes

 

C3

C3/C2

uMMA

uMCA

Hcy

(0.404.00 μmol/L)

(0.030.20)

(0.04.0 mmol/mol creatinine)

(0.00.8 mmol/mol creatinine)

(0.015 μmol/L)

 

Before treatment

After treatment

p1

Before treatment

After treatment

p1

Before treatment

After treatment

p1

Before treatment

After treatment

p1

Before treatment

After treatment

p1

Overall

7.13 (4.87–10.41)

3.43 (2.2–5.73)

<0.0001

0.6 (0.4–0.91)

0.14 (0.081–0.23)

<0.0001

114.3 (40.47–286.40)

7.2 (2.23–22.51)

<0.0001

3.13 (1.29–7.75)

0.79 (0–1.9)

0.0001

88.4 (51.09–148.9)

35.65 (23.6–48)

<0.0001

Subtypes

cblC

6.68 (4.63–9.52)

3.11 (2.02–4.81)

<0.0001

0.58 (0.39–0.9)

0.12 (0.08–0.18)

<0.0001

95.25 (37.00–237.20)

5.6 (1.89–15.38)

<0.0001

2.7 (1.1–5.79)

0.63 (0–1.42)

<0.0001

102.3 (65–162)

36.5 (25–49)

<0.0001

mut

9.82 (6.34–15.48)

12.75 (4.79–24.46)

0.0089

0.64 (0.47–0.95)

0.52 (0.24–0.74)

<0.0001

246 (98.09–558.30)

116.6 (12.21–409.6)

<0.0001

6.85 (2.26–16.55)

2.93 (0.85–6.75)

<0.0001

   

p2

<0.0001

<0.0001

 

0.027

<0.0001

 

<0.0001

<0.0001

 

<0.0001

<0.0001

    

NBS

               

Y(cblC)

6.78 (4.86–9.37)

2.70 (1.72–4.12)

<0.0001

0.57 (0.36–0.87)

0.1 (0.06–0.15)

<0.0001

82.80 (32.40–207.10)

4.35 (1.15–10.53)

<0.0001

2.6 (1.12–5.54)

0.44 (0–1.16)

<0.0001

105 (66.65–173.2)

33.53 (22.2–44.73)

<0.0001

N(cblC)

6.53 (4.46–9.66)

3.47 (2.38–5.21)

<0.0001

0.58 (0.39–0.91)

0.14 (0.1–0.21)

<0.0001

103.5 (36.29–258.40)

7.14 (2.78–20.00)

<0.0001

2.77 (1–5.92)

0.8 (0–1.67)

<0.0001

97.12 (63.28–146.7)

38.7 (26.6–52.9)

<0.0001

Y(mut)

7.49 (4.91–11.46)

6.68 (2.96–16.85)

0.78

0.57 (0.33–0.85)

0.30 (0.14–0.69)

<0.0001

127 (36.48–301.80)

27.79 (6.77–208.4)

<0.0001

4 (1.52–12.19)

1.6 (0.44–4.36)

<0.0001

   

N(mut)

11.49 (7.73–18.51)

18.25 (8.35–27.14)

0.0046

0.71 (0.51–1.02)

0.59 (0.38–0.78)

<0.0001

321.50

(152.5–734.3)

211.90 (48.94–617.00)

0.0009

8.615 (3.69–19.48)

4.4 (1.475–9.93)

0.0008

   

p3

>0.9999

<0.0001

 

>0.9999

<0.0001

 

0.43

<0.0001

 

>0.9999

<0.0001

 

0.16

<0.0001

 

p4

<0.0001

<0.0001

 

0.0034

<0.0001

 

<0.0001

0.0003

 

0.037

0.0005

    

p5

0.21

<0.0001

 

>0.9999

<0.0001

 

0.12

<0.0001

 

0.027

<0.0001

    

p6

<0.0001

<0.0001

 

0.001

0.0004

 

<0.0001

0.0008

 

<0.0001

0.0007

    
  1. p1: the differences of the corresponding metabolites levels before and after treatment; p2: the differences of the corresponding metabolites levels between cblC group and mut group; p3: the differences of the corresponding metabolites levels in cblC patients between NBS group and non-NBS group; p4: the differences of the corresponding metabolites levels in mut patients between NBS group and non-NBS group; p5: the differences of the corresponding metabolites levels in NBS group between cblC patients and mut patients; p6: the differences of the corresponding metabolites levels in non-NBS group between cblC patients and mut patients.
  2. C3 propionylcarnitine, C2 acetylcarnitine, uMMA urine methylmalonic acid, uMCA urine methylcitrate, Y yes, cblC or mut patients diagnosed by NBS; N no, cblC or mut patients diagnosed without NBS.